Top Tech Companies in Raleigh, NC (938)

Strong Revenue Growth: Galleri and total revenue have risen consistently, with full-year 2025 up 17% and U.S. Galleri up 26%, followed by Q1–Q2 2026 total revenue gains of 28% and 26% alongside 50% and 35% volume growth. This cadence, including Q4 2025 Galleri revenue up 31%, indicates sustained commercial momentum after the June 2024 spin‑off.

Strategic Partnerships: Channel and platform integrations such as Epic EHR and Quest Diagnostics, plus collaborations like Samsung for Asian commercialization, are expanding access and streamlining ordering. Additional distribution wins (e.g., Priority Health employer plans and digital health channels) reinforce multi‑channel penetration for Galleri.

Investor Backing & Capital Strength: The company reports a substantial cash balance (~$861.6M as of Q2 2026) and closed a $110M equity financing with Samsung, bolstering financial flexibility. Public listing post‑spin‑off further enhances capital‑markets access to fund trials and commercialization.

Resilient & Sustainable Growth: Revenue increased in FY2024 and again in FY2025 to a record ~US$56.9B, with all three lines of service expanding. Growth in the Americas and EMEA helped offset softness in parts of Asia Pacific, indicating steady, if modest, momentum.

Innovation-Driven Growth: A multi‑year push includes roughly US$1.5B to expand and scale AI capabilities, alongside AI‑enabled platforms and dedicated AI hubs/factories. These investments are positioned to extend growth beyond core assurance and tax and to support new, tech‑enabled offerings.

Strong Market Position & Advantage: As one of the Big Four with record scale and repeated “Leader” placements in independent analyst evaluations, the firm operates from a top‑tier competitive position. Rising brand value and leadership recognition in selected consulting categories reinforce commercial strength.

Investor Backing & Capital Strength: Recent financings include a strategic Series C with Dassault Syst�fsmes/Medidata (March 2025) and a Series D in April 2026 led by Boehringer Ingelheim tied to CT-155 commercialization. The restructuring with Boehringer also involved additional funding as commercialization responsibilities shifted to Click.

Product Line Growth: FDA authorizations for Rejoyn (MDD, 2024) and CT-132 (migraine prevention, 2025), plus the acquisition of AspyreRx (type 2 diabetes), expand the marketed and near-market portfolio. The launch of "Click SE" and CT-155s Breakthrough designation and positive pivotal data further broaden the offering toward potential submission.

Strategic Partnerships: Collaborations with Boehringer Ingelheim, Otsuka, and Dassault Syst�fsmes/Medidata, along with a 2026 venture with Ultrahuman, indicate strong external validation and routes to commercialization. Partner activity includes Boehringer transferring commercialization duties for CT-155 to Click.

Investor Backing & Capital Strength: BuildOps closed a $127M Series C in March 2025 at a $1B post‑money valuation, providing substantial capital to scale. Participation by top‑tier investors and the valuation step‑up indicate strong external confidence.

Strong Revenue Growth: Leadership stated revenue doubled in 2023 and 2024, and the company later appeared on the 2026 Inc. 5000 list, both pointing to sustained multi‑year expansion. Rising customer totals from 1,000+ to 1,500+ align with that trajectory.

Market Expansion: The company established a major hub in Raleigh and opened a dedicated Canadian HQ in Toronto in 2026, extending its geographic footprint. Reported headcount increases at these sites are consistent with scaling operations.

Strong Market Position & Advantage: Independent market-share analysis places Celonis at the front of its category while the market itself expands. This positioning suggests the company is capturing growth in a segment it leads.

Future-Ready Strategy: External recognition for long-term growth potential signals confidence in Celonis’s strategy, innovation, and talent pipeline. This points to preparedness as the space broadens from process mining into process intelligence and AI-enabled workflows.

Strategic Partnerships: A new alliance with a major data and AI platform provider expands product integrations and go-to-market reach into enterprise AI workflows. Such ecosystem momentum supports broader adoption and commercial expansion.

Strong Revenue Growth: Consolidated revenues increased from $253 billion in 2024 to $270.6 billion in 2025, with quarterly gains such as Q4 2025 up 8% year over year. Growth was led primarily by Optum Rx and supported by steady contributions from Optum Insight.

Market Expansion: Expansion through acquisitions such as Holston Medical Group (August 2025) and Alegeus (July 2026), alongside earlier combinations like Change Healthcare and Atrius Health, broadened capabilities across care, pharmacy, and payments. These moves extend Optum’s platform into adjacent services and operating domains.

Diversified Revenue Streams: A multi-segment model—Rx, Insight, and Health—helps sustain aggregate growth even as individual lines vary, with pharmacy and technology businesses offsetting care-delivery softness. Parent-company commentary continuing to frame Optum as a growth engine and raising 2026 guidance underscores the benefit of this portfolio effect.

Strong Revenue Growth: Revenue rose 13–15% year over year in Q1–Q2 2026, and guidance calls for full‑year 2026 growth of 10–13%, indicating sustained top‑line momentum.

Healthy Cash Flow: Operating cash flow of $94.6M and free cash flow of $87.7M in Q2 2026 point to solid cash generation that can support investment and capital returns.

Innovation-Driven Growth: AI‑driven dealer tools and a new consumer “Guru” layer are described as driving deeper engagement and higher monetization, alongside international growth.

Strong Market Position & Advantage: Independent analysts continue to place Qualtrics at the front of its market, with Gartner naming it a Leader in the Magic Quadrant for Voice of the Customer Platforms and positioning it highest on Ability to Execute and furthest on Completeness of Vision. This standing typically aligns with robust enterprise demand and supports commercial momentum.

Market Expansion: The company closed a $6.75 billion acquisition of Press Ganey Forsta on May 18, 2026, materially expanding its healthcare experience footprint and enlarging its data assets. Such scope increases are noted as common precursors to revenue growth and broader vertical penetration.

Innovation-Driven Growth: Qualtrics highlights rapidly expanding AI capabilities and analysis of billions of interactions annually, with usage of AI features surging and adoption widespread among large enterprise accounts. This product momentum supports upsell and cross‑sell into the installed base.

Strong Revenue Growth: Recent results show full-year 2025 revenue of about $3.05B up roughly 6% year over year, with Q1 2026 up 7.5% and Q2 2026 up ~5% year over year alongside mid‑single‑digit organic gains. Consistent quarterly execution through 2025 underscores steady top‑line momentum.

Profitability: Management reported record revenue with “impressive margin expansion” in Q2 2026, and adjusted EBITDA margin expanded earlier in 2026. Strong operating cash generation in 2025 further supports the improving earnings profile.

Innovation-Driven Growth: New launches such as AI‑enabled sustainability software (ULTRUS 360), building‑compliance software, and certifications for AI‑enabled products and hydrogen fueling components indicate investment in adjacent, faster‑growing niches. These moves align the portfolio with regulation‑ and sustainability‑driven demand.

Strong Revenue Growth: Consecutive Inc. 5000 placements in 2023 and 2024 and the company’s statement that it doubled revenue between 2019 and 2022 point to sustained top-line momentum over recent multi-year periods.

Investor Backing & Capital Strength: A February 27, 2025 growth‑equity investment from Boathouse Capital is explicitly earmarked to scale hiring, expand services and enter new markets, and potentially support M&A.

Market Expansion: Expansion moves such as acquiring Mashey, establishing an international team in Bulgaria, and enlarging its Chicago headquarters indicate a deliberate scale‑up of footprint and delivery capacity.

Strong Market Position & Advantage: Carrier is consistently described as a top‑three global HVAC player and a long‑time share leader in North America. Commercial HVAC orders and data‑center demand indicate momentum in key higher‑value segments.

Future-Ready Strategy: The portfolio has been reshaped into a pure‑play climate company through the Viessmann Climate Solutions acquisition, expanding European heat‑pump and residential exposure. These moves concentrate the business on energy‑transition areas such as heat pumps and integrated home energy systems.

Healthy Cash Flow: Free cash flow generation remained strong, with approximately $0.9 billion in Q4 2025. Capital deployment plans including share repurchases indicate ongoing liquidity and financial flexibility.

Market Expansion: Expansion via acquisitions and brownfield/greenfield openings continued, with milestones like surpassing 1,000 locations and the closing of the Joe Hudson’s deal. Reaffirmed objectives to increase market share and a robust new‑store pipeline point to sustained footprint growth.

Strong Market Position & Advantage: Industry updates consistently place the company among the top multi‑shop operators by scale, with a network expanded to about 1,301 North American locations post‑acquisition. Scale advantages are described as important for insurer program volume, procurement leverage, and technician development.

Investor Backing & Capital Strength: Capital access was strengthened through a U.S. listing, equity raise, senior notes, and expanded credit facilities. Disclosures indicate these funds supported the Joe Hudson’s acquisition and ongoing development activity.

Investor Backing & Capital Strength: A growth-oriented private equity investment from New Mountain Capital (with minority investments from CDPQ and OA Private Capital) in 2024 supplied an “investment war chest” to accelerate technology, AI-enabled services, talent acquisition, and strategic expansion. This capital base also underpins the multinational platform strategy and the announced CBIZ deal.

Market Expansion: Grant Thornton Advisors announced a $5.0 billion acquisition of CBIZ that, upon closing, would lift the U.S. platform past $5 billion in domestic revenue and expand brand reach. The Advisors arm also combined with Grant Thornton Ireland in 2025 and has since grown its European footprint, signaling inorganic and international momentum.

Strong Market Position & Advantage: The firm is consistently ranked among the top U.S. accounting and professional services firms, operates across numerous U.S. offices, and is a premier leader for the mid‑market and private‑equity segments. Its inclusion among the small set of firms subject to annual PCAOB inspection underscores national scale and capital‑markets relevance.